Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Veterinary Clinics: Small Animal PracticeAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.Cochrane Database Syst Rev. 2020; (CD005613)
- Basal-bolus insulin therapy and glycemic control in adult patients with type 2 diabetes mellitus: a review of the literature.J Am Assoc Nurse Pract. 2014; 26: 348-352
Toujeo. Package insert. Sandofi-Aventis U.S. LLC; 2015.
- Time-action profiles of insulin degludec in healthy dogs and its effects on glycemic control in diabetic dogs.J Vet Med Sci. 2018; 80: 1720-1723
- Comparison of the pharmacodynamics of protamine zinc insulin and insulin degludec and validation of the continuous glucose monitoring system iPro2 in healthy cats.Res Vet Sci. 2018; 118: 79-85
- Day-to-day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs.J Vet Intern Med. 2021; 35: 2131-2139
- Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats.Domest Anim Endocrinol. 2021; 75: 106595
- Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing.BMJ Open Diabetes Res Care. 2021; 9: e002301
- Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans.J Med Chem. 2021; 64: 8942-8950
- (LAPS) Insulin115: a novel ultra-long-acting basal insulin with a unique action profile.Diabetes Obes Metab. 2017; 19: 1722-1731
- An ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in cats.J Vet Intern Med. 2021; 35: 2123-2130
- Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs.J Vet Intern Med. 2022; 36: 1211-1219
- New approaches to feline diabetes mellitus: glucagon-like peptide-1 analogs.J Feline Med Surg. 2016; 18: 733-743
- Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.Res Vet Sci. 2013; 95: 381-388
- Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.Metabolism. 2014; 63: 9-19
- Standards of medical care in diabetes-2022 abridged for primary care providers.Clin Diabetes. 2022; 40: 10-38
- Effect of the glucagon-like peptide-1 analogue exenatide extended release in cats with newly diagnosed diabetes mellitus.J Vet Intern Med. 2016; 30: 92-100
- Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus.Domest Anim Endocrinol. 2018; 65: 80-89
- The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats.Domest Anim Endocrinol. 2011; 41: 42-49
- Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats.Res Vet Sci. 2015; 99: 23-29
- Effects of a glucagon-like peptide-1 mimetic (exenatide) in healthy cats.Intern J Appl Res Vet Med. 2012; 10: 147-156
- DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.J Clin Endocrinol Metab. 2011; 96: 1301-1310
- Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.Domest Anim Endocrinol. 2015; 51: 78-85
- Effect of monthly injections of GLP-1 analogue exenatide extended release on beta-cell function in newly diagnosed diabetic cats.J Vet Intern Med. 2019; 33 (Abstract): 1042-1043
- Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release.J Vet Intern Med. 2020; 34: 2287-2295
- A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.Domest Anim Endocrinol. 2020; 70: 106373
- Safety and tolerability of OKV-119: a novel exenatide long-term drug-delivery-system in cats.J Vet Intern Med. 2021; 35 (Abstract): 3026
- The discovery and development of liraglutide and semaglutide.Front Endocrinol. 2019; 10: 155
- Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats.Domest Anim Endocrinol. 2015; 51: 114-121
- Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.Regul Pept. 2010; 164: 58-64
- Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog.Am J Physiol Endocrinol Metab. 2013; 305: E1473-E1482
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).Diabetes Care. 2014; 37: 2168-2176
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.Lancet Diabetes Endocrinol. 2014; 2: 289-297
- Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial.J Am Med Assoc. 2019; 321: 1466-1480
Rybelsus. Package insert. Novo Nordisk Inc.; 2019.
- Role of dipeptidyl peptidase 4 inhibitors in antidiabetic treatment.Molecules. 2022; 27: 3055
- Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like peptide 1 infusion increases liver glucose uptake in the conscious dog.Diabetes. 2009; 58: 243-249
- SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.Lancet. 2021; 398: 262-276
- The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats.Vet J. 2010; 183: 355-357
- Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.Eur J Pharmacol. 2008; 589: 306-314
- Effect of acarbose, sitagliptin and combination therapy on blood glucose, insulin, and incretin hormone concentrations in experimentally induced postprandial hyperglycemia of healthy cats.Res Vet Sci. 2016; 106: 131-134
- Preliminary study characterizing the use of sitagliptin for glycemic control in healthy Beagle dogs with normal gluco-homeostasis.J Vet Med Sci. 2014; 76: 1383-1387
- Comparing the 5-Year diabetes outcomes of sleeve gastrectomy and gastric bypass: the national patient-centered clinical research network (PCORNet) Bariatric Study.JAMA Surg. 2020; 155: e200087
- Laparoscopic vertical sleeve gastrectomy in felines: a cadaveric feasibility study and experimental case series in two cats.Vet Surg. 2022; https://doi.org/10.1111/vsu.13862
- Treatment of type 2 diabetes: challenges, hopes, and anticipated successes.Lancet Diabetes Endocrinol. 2021; 9: 525-544
- Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review.JACC Basic Transl Sci. 2020; 5: 632-644
- Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.Drug Metab Dispos. 2014; 42: 903-916
- Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats.J Vet Pharmacol Ther. 2018; 41: 266-273
- The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats.Domest Anim Endocrinol. 2020; 70: 106376
- Salt and sugar in your larder make your kidneys work harder.J Vet Intern Med. 2019; 33 (Abstract): 1096
- Isolated renal glycosuria does not lead to polyuria in a feline model.J Vet Intern Med. 2018; 32 (Abstract): 2224-2225
- Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus.Can J Vet Res. 2022; 86: 52-58
- Once-daily oral therapy for feline diabetes mellitus: SGLT-2-inhibitor velagliflozin as standalone therapy compared to insulin injection therapy in diabetic cats. September 2022; 1-3
- Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.Diabetes Obes Metab. 2017; 19: 348-355
- Quality of life and treatment satisfaction in adults with type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections.Diabet Med. 2008; 25: 213-220
- Evaluation of a quality-of-life tool for cats with diabetes mellitus.J Vet Intern Med. 2010; 24: 1098-1105
- Evaluation of a quality-of-life tool for dogs with diabetes mellitus.J Vet Intern Med. 2012; 26: 953-961
Afrezza. Package insert. MannKind Corporation; 2014.
- Glucose lowering effects of inhaled insulin in healthy cats.J Feline Med Surg. 2008; 10: 519-522
- Non-invasive ways of administering insulin.Diabetes Metab Syndr. 2022; 16: 102478
- Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.Lancet Diabetes Endocrinol. 2019; 7: 179-188
- Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes: a randomized, placebo-controlled trial.Diabetes Obes Metab. 2021; 23: 2529-2538
- Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models.J Diabetes Sci Technol. 2010; 4: 1516-1523
- HbA1c, and less hypoglycemia in closed-loop insulin system in patients with type 1 diabetes: a meta-analysis.BMJ Open Diabetes Res Care. 2022; 10: e002633
- Tissue Response to subcutaneous infusion catheter.J Diabetes Sci Technol. 2020; 14: 226-232
- Smart' insulin-delivery technologies and intrinsic glucose-responsive insulin analogues.Diabetologia. 2021; 64: 1016-1029
- The review of insulin pens-past, present, and look to the future.Front Endocrinol. 2022; 13: 827484
- Medical devices, smart drug delivery, wearables and technology for the treatment of diabetes mellitus.Adv Drug Deliv Rev. 2022; 185: 114280
- Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.Lancet Diabetes Endocrinol. 2015; 3: 17-26
- Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial.Diabetologia. 2016; 59: 2561-2571
- New horizons: next-generation insulin analogues: structural principles and clinical goals.J Clin Endocrinol Metab. 2022; 107: 909-928
- Improved yield of canine islet isolation from deceased donors.BMC Vet Res. 2017; 13: 264
- Concise review: canine diabetes mellitus as a translational model for innovative regenerative medicine approaches.Stem Cells Transl Med. 2019; 8: 450-455
- PEGDA microencapsulated allogeneic islets reverse canine diabetes without immunosuppression.PLoS One. 2022; 17: e0267814
- Stem cell transplantation in the treatment of type 1 diabetes mellitus: from insulin replacement to beta-cell replacement.Front Endocrinol. 2022; 13: 859638
Article info
Publication history
Published online: February 26, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
